MA
EBS icon

MCF Advisors’s Emergent Biosolutions EBS Stock Holding History

MCF Advisors’s Portfolio EBS Stock Details EBS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-10
Closed -$89 – 1148
2025
Q3 		$89 Hold
10
– – ﹤0.01% 951
2025
Q2 		$64 Hold
10
– – ﹤0.01% 882
2025
Q1 		$49 Hold
10
– – ﹤0.01% 892
2024
Q4 		$96 Hold
10
– – ﹤0.01% 974
2024
Q3 		$84 Hold
10
– – ﹤0.01% 986
2024
Q2 		$69 Buy
+10
New +$43 ﹤0.01% 1007

Other funds holding EBS

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
OHA
Oak Hill Advisors New York $701M AUM 78.4% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Charles Schwab
Charles Schwab San Francisco, California $751B AUM 38.74% 1-Year Est. Return
PCM
Palisade Capital Management Fort Lee, New Jersey $2.3B AUM 29.92% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

MCF Advisors's EBS Position: Q4 2025 in Review

MCF Advisors sold out of Emergent Biosolutions (EBS) in Q4 2025, closing a stake of 10 shares — an estimated $89 sold.

MCF Advisors first reported a position in EBS in Q2 2024 and held it in 6 quarters. The position peaked at $96 in Q4 2024. 183 funds tracked by Wall St. Rank hold EBS as of Q4 2025.

  • MCF Advisors reported no remaining Emergent Biosolutions position as of Q4 2025 after selling out during the quarter.
  • MCF Advisors sold 10 Emergent Biosolutions shares in Q4 2025, an estimated $89.
  • MCF Advisors first reported a position in Emergent Biosolutions in Q2 2024 and held it in 6 quarters.
  • MCF Advisors's Emergent Biosolutions position peaked at $96 in Q4 2024.
  • 183 funds tracked by Wall St. Rank held Emergent Biosolutions as of Q4 2025.

Based on MCF Advisors's 13F filing for Q4 2025, filed 11 Feb 2026.